BTIG analysts estimate that Elutia’s Elupro and Medtronic’s TYRX are competing for a $600 million opportunity in the U.S. cardiac rhythm management sector.
Boston Scientific inks $88M Elutia deal to challenge Medtronic
BTIG analysts estimate that Elutia’s Elupro and Medtronic’s TYRX are competing for a $600 million opportunity in the U.S. cardiac rhythm management sector.